Paul Thomen

Friday, 2 August 2013

Opportunities in Human Embryonic Stem Cell Products Market

The report Opportunities in Human Embryonic Stem Cell Products by BioInformant Worldwide, L.L.C. is now available at Contact with Opportunities in Human Embryonic Stem Cell Products in subject line and your contact details to purchase this report or get your questions answered.

Human embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, which is a stage reached four to five days post-fertilization. Human embryonic stem cells are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body.

Human embryonic stem cells were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of embryonic stem cells from non-human primates occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow hESCs derived from human blastocysts. Federal funds to support hESC research became available on August 9, 2001, when President Bush announced his decision regarding federal funding for hESC research.

Because of their plasticity and unlimited capacity for self-renewal, hESCs have been proposed for use in wide range of applications, including toxicology testing, tissue engineering, cellular therapies, and basic stem cell biology research. Of particular interest to the medical community is the potential for use of hESCs to heal tissues with naturally limited capacity for renewal, such as the human heart, liver and brain.

However, human embryonic stem cell research is heavily encumbered by patents held by the University of Wisconsin’s Wisconsin Alumni Research Foundation (WARF), which creates significant challenges for companies seeking to develop new products.

This market research report explores the complex IP landscape affecting development of human embryonic stem cell products, providing clear guidance for companies entering or already within the market, from collaborating with WARF to less costly alternatives – such as circumventing the claims, conducting research off-shore, and developing embryonic stem cell products for other species.

Key Findings Include:
- Trends for hESC Grants, Scientific Publications, and Patents
- Market Size Determination for the hESC Product Market
- 5-Year Market Size Projections (2013-2017)
- Embryonic Stem Cell Patent Restrictions and Strategies to Circumvent Claims
- Geographical Breakdown (Leading Countries Conducting hESC Research)
- Breakdown of Embryonic Stem Cell Research, by Application and Species
- Competitive Analysis of hESC Research Supply Vendors
- Overview of Specialty Pharma Companies Developing Embryonic Stem Cell Therapies
- Overview of Toxicology Testing Legislation (impacting use of hESC in toxicology applications)
- Crucial Trends and Unmet Market Needs
- And Much More

The potential medical advances made possible from the use of human embryonic stem cells (hESC) are huge, so it is no surprise that the scientific research community is enthusiastically exploring all possibilities.
Where there is significant and growing interest from scientists, there is an opportunity to increase revenue from hESC products. There is no doubt it’s an exciting market in which to expand your product range, but with embryonic stem cells there are serious market entry barriers to consider – namely a complex intellectual property scene.

This report will help you understand the market entry challenges you face and give you the expert advice to overcome them. Couple this with market leading intelligence data and this report is a must have if you’re looking to outcompete your rivals in this expanding and highly profitable market.

Navigating the Intellectual Property Landscape: Making the Complex Simple
Human embryonic stem cell research is restricted by patents held by the University of Wisconsin’s Wisconsin Alumni Research Foundation (WARF), which creates significant challenges for companies looking to develop products to supply this part of the stem cell research market.

The intellectual property (IP) issues for companies wishing to enter the market are such a barrier to entry that knowledge of how to overcome the problem becomes extremely valuable. The complex IP landscape requires specialist industry knowledge to help you navigate the legal and commercial challenges you will face. With simple and expert advice, you will understand:
- The background of the patent landscape
- The licensing of WARF patent rights
- WARF patent exceptions
- How to circumvent WARF patents rights through geographic limitations
- The global stem cell patent landscape
- And much more

Explorer More Reports of Medical Devices Market @

Major Points in a Table of Content

VII. hESC Product Competitors
A. Cellartis AB
1. Human embryonic stem cell lines
2. Monoclonal Antibodies for hESC Research
3. Differentiated Cell Products
4. Associated hESC products
B. Vitrolife
C. Tataa Biocenter
D. Invitrogen
1. hESC Culture Media & Reagents
2. hESC-qualified Basement Membrane Extract
3. hESC cDNA Libraries
4. hESC Reporter Cells
5. hESC PCR Kits
6. hESC Stem Cell Antibodies
7. hESC Stem Cell Growth Factors
E. Stem Cell Technologies
1. hESC Culture Media & Reagents
2. hESC Primary & Secondary Antibodies
F. BD Biosciences
G. Chemicon
1. hESC Culture Media and Reagents
2. hESC Lines
3. hESC Kits
4. hESC Antibodies
H. R&D Systems
I. SA Biosciences
J. Thermo Scientific
K. Australian Stem Cell Centre

No comments:

Post a Comment

Note: only a member of this blog may post a comment.